

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

COMP/M. 4704 - BRIDGEPOINT / GAMBRO HEALTHCARE

SECTION 1.2

Description of the concentration

1.2 Provide a summary (up to 500 words) of the information provided under Section 1.1. It is intended that this summary will be published on the Commission's website at the date of notification. The summary must be drafted so that it contains no confidential information or business secrets.

On 23 May 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) 139/2004 by which the undertaking Bridgepoint Capital Limited, through Velox Bidco S.A.R.L., a company directly controlled by it, proposes to acquire, within the meaning of Article 3(1)(b) of the Council Regulation, sole control of Gambro Healthcare by way of purchase of shares.

The business activities of the undertakings concerned are:

- (i) For Bridgepoint Capital Group Limited: a private equity company which invests in companies active in various sectors.
- (ii) For Gambro Healthcare: a provider of kidney dialysis clinic services.

The transaction will not have an appreciable effect on any market.